Guanylate-binding protein 3 (GBP3) (GBP3)

Guanylate-binding protein 3 (GBP3) is an interferon-inducible large GTPase belonging to the dynamin-related superfamily, primarily recognized for its role in the host's innate immune defense (UniProt: P32455). It functions by hydrolyzing GTP to facilitate the assembly of supramolecular complexes that disrupt the membranes of intracellular bacteria and viruses, thereby restricting their replication and signaling for inflammasome activation (PubMed: 2635). In the field of oncology, GBP3 has emerged as a significant prognostic marker and potential therapeutic target, particularly in glioblastoma multiforme and colorectal cancer, where its overexpression is linked to increased tumor cell proliferation, migration, and poor clinical outcomes (PubMed: 32854145, 30106343). While no small-molecule inhibitors are currently approved for clinical use, research has demonstrated that targeting GBP3 mRNA with small interfering RNAs (siRNAs) can effectively reduce protein levels and inhibit tumor progression in preclinical models. Consequently, GBP3 is being investigated as a target for RNA-based therapies designed to suppress oncogenic signaling or modulate immune responses. However, therapeutic strategies must carefully balance the benefits of tumor suppression against the potential risk of compromising the host's ability to defend against intracellular infections.

Other names

Guanine nucleotide-binding protein 3GTP-binding protein 3GBP-3

Inhibition of gene expression through RNA interference (siRNA) or antisense oligonucleotides (ASOs) targeting the mRNA transcript to downregulate protein levels.